p-ErbB2/HER2 Antibody (14C3): sc-81506

p-Neu Antibody (14C3) is a mouse monoclonal IgG1 antibody that detects Neu in human samples through western blotting (WB). Neu, also known as v-ErbB-2 erythroblastic leukemia viral oncogene homolog 2 or HER2, plays a critical role in cell signaling pathways that regulate cell growth and differentiation, making Neu a significant factor in the development of various cancers, including breast, gastric, and esophageal cancers. Neu is primarily located in the cell membrane, where Neu interacts with other proteins to form signaling complexes essential for normal cellular function. Notably, Neu undergoes post-translational modifications, such as phosphorylation at specific tyrosine residues, which are crucial for activity and interactions. For instance, phosphorylation at Tyr 1248 facilitates Neu localization with the Mucin4/Sialomucin complex at the apical surfaces of ductal and alveolar cells, highlighting Neu′s importance in tissue architecture and function. Additionally, Neu phosphorylation at Tyr 1139 promotes association with GRB2 and GRB7, which are vital for downstream signaling pathways that can lead to tumorigenesis. Neu′s ability to undergo these modifications and interact with various signaling proteins underscores Neu′s role as a key player in oncogenic processes, making anti-Neu antibody (14C3) an invaluable tool for researchers studying cancer biology and therapeutic targets.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

p-ErbB2/HER2 Antibody (14C3) References:

1. Muc4/sialomucin complex, an intramembrane modulator of ErbB2/HER2/Neu, potentiates primary tumor growth and suppresses apoptosis in a xenotransplanted tumor.  |  Komatsu, M., et al. 2001. Oncogene. 20: 461-70. PMID: 11313977
2. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation.  |  Zhou, BP., et al. 2001. Nat Cell Biol. 3: 973-82. PMID: 11715018
3. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.  |  Shou, J., et al. 2004. J Natl Cancer Inst. 96: 926-35. PMID: 15199112
4. Phosphoproteomic analysis of Her2/neu signaling and inhibition.  |  Bose, R., et al. 2006. Proc Natl Acad Sci U S A. 103: 9773-8. PMID: 16785428
5. Stat1 is a suppressor of ErbB2/Neu-mediated cellular transformation and mouse mammary gland tumor formation.  |  Raven, JF., et al. 2011. Cell Cycle. 10: 794-804. PMID: 21311224
6. Correlation of phosphorylated HER2 with clinicopathological characteristics and efficacy of trastuzumab treatment for breast cancer.  |  Ramić, S., et al. 2013. Anticancer Res. 33: 2509-15. PMID: 23749902
7. HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor.  |  English, DP., et al. 2013. Gynecol Oncol. 131: 753-8. PMID: 24012800
8. Intratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cells.  |  Masuelli, L., et al. 2014. J Transl Med. 12: 122. PMID: 24886178
9. Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo.  |  Menderes, G., et al. 2017. Med Oncol. 34: 91. PMID: 28397106
10. Selective inhibition of the epidermal growth factor and HER2/neu receptors by tyrphostins.  |  Osherov, N., et al. 1993. J Biol Chem. 268: 11134-42. PMID: 8098709

The preferred antibody is Antibody (): sc-8.